















































































































































	 n mean	delay 95%	CI I2
World	Health	Organisation	regions
European 34 7.02 6.31,	7.73 98.2%
West	Pacific 7 6.43 4.49,	8.37 96.8%
Eastern
Mediterranean
7 6.62 5.37,	7.88 90.4%
Americas 4 5.76 2.63,	8.89 98.7%
South	East	Asia 3 6.38 -1.40,	14.15 96.7%
World	Bank	economic	class
High 34 7.61 7.03,	8.18 97.4%
Upper	middle 16 5.38 4.46,	6.30 96.8%
Lower	middle 5 5.59 3.21,	7.96 95.7%
Countries	with	≥3	studies
UK 8 8.69 7.14,	10.23 94.9%
Turkey 8 5.54 4.39,	6.68 90.4%
Italy 3 7.68 2.67,	12.69 99.6%
Iran 3 7.35 4.83,	9.87 79.5%
China 3 4.61 1.47,	7.75 85.6%
Recruiting	methods
Single	centre 32 6.60 5.84,	7.36 98.5%
>1	centre 23 7.02 6.23,	7.83 98.8%
Year	of	publication	
<2010 8 7.08 5.87,	8.30 95.4%
2010-15 25 6.82 5.93,	7.70 97.3%











22.7	-	24.2	years 10 7.37 6.11,	8.64 98.0%
24.4	-	27.1	years 11 7.70 6.59,	8.81 94.5%
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27.3	-	35	years 11 6.33 4.50,	8.16 99.1%
Proportion	of	males	(tertiles)
39-68% 17 7.05 6.09,	8.01 98.7%
68-80% 17 7.52 6.55,	8.48 95.0%
80-100% 18 5.70 4.91,	6.48 94.8%
	
Factors	associated	with	delay	to	diagnosis
Most	results	were	from	unadjusted	comparisons	(table	2).	Delay	was	reportedly	longer	in	males	in
studies	by	Bandinelli	(10	v	6.3	years,	p=0.002)	and	Sykes	(9.4	v	8.3,	p=0.097)	[4,14],	but	longer	in
females	in	studies	by	Fallahi	(8.7	v	7.7,	p=0.68),	Dincer	(14	v	5.3,	p=0.06),	Hajialilo	(8.0	v	5.9,
p=0.14),	Jones	(8.5	v	5.6)	and	Redeker	(by	1.9yrs,	p<0.05)	[15–19],	albeit	mostly	not	statistically
significant.	Similarly,	2	studies	reported	longer	delay	in	those	with	peripheral	arthritis	[15,17],	while	5
reported	longer	delays	in	those	without	[4,6,14,20,21].	There	was	also	inconsistency	in	whether
studies	found	HLA-B27	status	to	be	associated	with	diagnostic	delay:	4	studies	reported	significantly
longer	delays	in	HLA-B27	negative	patients	[15,16,19,22],	while	5	other	studies	did	not
[14,20,21,23,24].
There	was	better	consensus	among	the	studies	that	longer	delay	was	associated	with:	the	absence	of
EAMs	[4,17,23],	lower	education	[15,16,20,25],	and	younger	age	of	onset	[19,20,24,25].
Table	2	Factors	associated	with	longer	delay	to	diagnosis	in	axial	spondyloarthritis	(results	reported	as	mean	duration	in
years).
Aggarwal	2009	[23] Absence	EAMs	v	presence	(8.7	vs	5.9,	p=0.03)
Onset	<16	v	>16	yrs	(9.1	v	6.1,	p=0.03)
Bandinelli	2016	[14] Male	v	females	(10	vs	6.3,	p=0.002)
Manual	v	non-manual	workers	(11	vs	8.3,	p=0.047)
Axial	presentations	compared	to	arthritis	or	enthesitis	(9.0	vs
8.5	vs	4.3,	p=0.002)
Lower	education	(<high	school	v	high	school	v	university:	10
v	8.6	v	7.3,	p=0.076)
Dincer	2008	[16] HLA-B27	negative	v	positive	(9.2	vs	5.3,	p=0.037)
Family	history	v	none	(10	vs	4.6	p=0.003)
Onset	≤16	v	>16	yrs	(8.9	v	5.5,	p=0.027)
Lower	education	(<9yrs	v	9-11	v	12-13	v	14-15:	12	v	6.3	v
5.0	v	4.6,	p=0.018)
Females	v	males	(14	v	5.3,	p=0.061)
Fallahi	2016	[15] Enthesitis	v	no	enthesitis	(8.8	vs	6.0,	p=0.007)
HLA-B27	negative	v	positive	(10	vs	7.1,	p=0.013)
Lower	education	(correlation	r=0.24	p=0.002)
Presence	of	peripheral	arthritis	v	absence	(8.9	v	6.8,
p=0.086)
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Feldtkeller	2003	[22] HLA-B27	negative	v	positive	(11	v	8.5,	p<0.01)
Gerdan	2012	[25] With	v	without	prior	diagnosis	of	lumbar	disc	herniation	(9.1
vs	6.2,	p=0.002)
First	contact	being	rheumatology	v	non-rheumatology	(8.1	vs
2.9,	p<0.001)
Younger	age	at	onset	(b=-0.18,	p=0.003)
Lower	education	(b=-0.252,	p=0.018)
Hajialilo	2014	[17] Presence	of	peripheral	arthritis	v	absence	(11	vs	5.1
p<0.001)
Absence	of	uveitis	v	presence	(6.4	v	2.4	p=0.02)
Presence	of	heal	pain	v	absence	(13	v	5.9	p=0.004)
Females	v	males	(8.0	v	5.9,	p=0.14)
Jones	2014	[18] Females	v	males	(8.5	vs	5.6)
Masson	Behar	2017	[20] Univariable	regression	showed	longer	delay	with	
Older	age	at	diagnosis	(b=0.15	p<0.001)
Lower	education	(b=-1.7	p=0.03)
Later	calendar	year	of	diagnosis	(0.1	p=0.005)
Multivariable	regression	showed	longer	delay	with
Older	age	at	diagnosis	(b=0.1,	p<0.001)
Entheseal	pain	v	none	(b=1.5	p=0.015)
Absence	of	peripheral	arthritis/dactylitis	v	presence	(b=-1.7,
p=0.005)
Nakashima	2016	[21] Absence	articular	involvement	vs	presence	(8.9	v	5.2,
p=0.03)
Disease	onset	pre-2000	v	post	(7.5	v	3.5	p=0.02)
Reed	2008	[26] Delay	longer	with	later	calendar	year	and	younger	age	at
onset	(p<0.05)
Seo	2015	[6] Long-delay	(v	short	delay	<=8	years)	category	associated
with:
Absence	of	peripheral	symptoms	(OR	2.2,	p=0.06)	
Prior	diagnosis	of	mechanical	back	pain	(OR	2.8,	p=0.02)
In	univariate	analysis,	mechanical	back	pain	remained
significant	in	multivariable	model
Sykes	2015	[4] Absence	of	peripheral	arthritis	vs	presence	(9.4	v	7.6,
p=0.045)
Absence	of	IBD	v	presence	(9.2	v	6.5,	p=0.012)
Presence	of	uveitis	vs	absence	(10	v	8.4,	p=0.033)
Females	v	males	(9.4	v	8.3,	p=0.097)
Redeker	2018	(abstract)	[19] Multivariable	regression	showed	longer	delay	in
Female	v	males	(b=1.9,	95%CI	1.1	2.7)
Younger	age	of	symptom	onset,	per	10yrs	(-1.9,	95%CI	-2.3,
-1.5)
HLA-B27	negative	v	positive	(-3.6,	95%CI	-5.1,	-2.1)
Psoriasis	v	no	psoriasis	(1.4,	95%CI	0.1,	2.7)
Resende	2018	(abstract)	[24] Presence	of	EAMs	v	absence	(8.7	v	5.0,	p<0.001)
Younger	age	onset	(r=-0.28,	p<0.001)
EAM,	extra-articular	manifestations	(anterior	uveitis,	psoriasis,	inflammatory	bowel	disease)
	
PsA	and	SpA
Sample	size	for	PsA	studies	ranged	from	69	to	1970	patients.	Diagnostic	delay	ranged	from	1.0	years
in	the	Dutch	South-West	Psoriatic	Arthritis	to	4.6	in	a	Swedish	population-based	cohort	[27,28].	The
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mean	delay	to	PsA	diagnosis	was	2.6	years	(95%CI	1.6	to	3.6,	I2=99%)	(Figure	2).	SpA	studies	ranged
from	16	to	275	participants	in	size	and	1.6	to	7.6	years	in	diagnostic	delay.	The	mean	delay	to	SpA
diagnosis	was	4.2	years	(95%CI	2.1	to	8.1,	I2=96%)	(Figure	2).
	
Discussion
The	mean	delay	to	diagnosis	was	6.8	years	across	54	axSpA	studies	worldwide.	Interestingly,
countries	classed	as	high-income	by	the	World	Bank	had	significantly	longer	delays	to	diagnosis	than
medium-income	countries.	Factors	associated	with	delay	to	diagnosis	varied	and	were	often
contradictory	across	studies;	the	most	consistently	reported	factors	were	lower	education,	absence	of
extra-articular	manifestations	and	younger	age	of	onset.	Diagnostic	delay	in	axSpA	was	significantly
longer	than	in	PsA	(2.6	years)	and	when	SpA	were	combined	(4.2	years).
Mean	duration	of	delay	varied	significantly	within	(e.g.,	from	5.7	to	11	years	in	the	UK	and	3.7	to
8.1	years	in	Turkey)	and	between	countries.	This	may	reflect	multiple	factors	that	could	not	be
assessed	in	this	review,	such	as	local	healthcare	infrastructure	and	awareness	of	the	disease.	Our
finding	that	delay	was	longer	in	high-income	countries	was	unexpected.	It	may	be	that	research
centres	in	these	countries	received	referrals	for	the	most	diagnostically	challenging	cases	or	served
comparably	deprived	areas.	Conversely,	it	may	be	that	only	centres	with	good	referral	infrastructure
are	publishing	research	in	middle-income	countries.
Our	meta-analysis	showed	no	meaningful	change	in	diagnostic	delay	over	time.	This	is	consistent	with
results	from	the	UK	[4,29],	France	[20]	and	Germany	[19].	In	stark	contrast,	delay	to	diagnosis
improved	dramatically	in	Japan	(pre-	v	post-2000:	7.5	v	3.6	years	[21]),	Italy	(1990s	v	2000s:	7.4	v
2.1	years	[30]),	Denmark	(2000	v	2011:	5.5	v	0.3	years	[11]),	Egypt	(pre-	v	post-2010:	11	v	4.6	years
[31])	and	Australia	[26].	We	could	not	examine	the	cause	of	this	variation	in	detail,	but	diagnostic
approaches	likely	varied	from	country	to	country.	For	example,	the	extent	to	which	HLA-B27	and
gender	were	associated	with	delay	differed	between	countries,	suggesting	that	these	factors	may
have	differential	importance	in	their	respective	diagnostic	process.
Inflammatory	back	pain	in	axSpA	typically	has	an	insidious	onset,	with	subtle	signs	on	clinical
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examination.	There	is	also	a	plethora	of	highly	prevalent	differential	diagnoses	that	may	be
incorrectly	used	to	explain	symptoms;	for	example,	lumbar	disc	disease	can	co-exist	with	axSpA	and
prolong	delay	to	diagnosis	[6,25].	Peripheral	joint	involvement	is	relatively	more	acute	in
presentation,	with	clearer	signs	such	as	swelling	and	erythema.	This	may	explain	the	much	shorter
diagnostic	delay	in	PsA	than	in	axSpA.	Among	axSpA	studies,	the	presence	of	peripheral	joint
involvement	was	associated	with	shorter	delay	to	diagnosis	in	Italian	[14],	UK	[4],	French	[20]	and
Japanese	[21]	studies,	while	these	patients	had	longer	delays	in	Iran	[15,17].	It	may	be	the	case	that
these	Iranian	patients	were	given	other	diagnoses	prior	to	the	correct	axSpA	label.
To	reduce	delay	to	diagnosis,	intuitive	targets	would	be	to	improve	awareness	of	axSpA	as	a	cause	of
back	pain;	general	education	was	inversely	associated	with	delay.	Younger	age	of	onset	was	also
consistently	associated	with	prolonged	delay.	(Although	this	may	be	an	artefact	of	“delay”	being
derived	from,	and	being	dependent	on,	age	at	onset.)	Education	is	needed	among	non-
rheumatologists	that	axSpA	is	a	cause	of	back	pain	in	young	people.	However,	there	will	be	cases	that
remain	more	diagnostically	challenging,	such	as	patients	with	few	SpA	features.
A	key	strength	of	this	review	is	the	large	and	globally	representative	number	of	studies.	There	were
however	limitations.	Diagnostic	delay	is	known	to	be	right-skewed	in	distribution,	meaning	that	the
mean	is	inflated	above	the	median	by	a	high	proportion	of	people	with	disproportionately	long	delays.
In	other	words,	the	mean	may	be	sensitivity	to	these	outliers	(e.g.,	atypical	clinical	features	or
individuals	with	poor	access	to	healthcare)	and	remain	unchanged,	even	if	diagnostic	delay	generally
improved	for	many	patients.	We	chose	mean	firstly	because	it	permits	meta-analysis,	but	also
because	median	would	take	emphasis	away	from	those	with	unusually	long	delays	-	precisely	the
individuals	needing	improvement	to	diagnosis.	Some	meta-analysis	estimates	for	delay	had	negative
lower-bounds	in	the	confidence	interval,	which	is	not	possible	by	definition.	This	is	an	artefact	of	the
random-effects	methodology;	in	each	case,	there	is	one	study	with	a	much	shorter	delay	than	others
in	the	category,	resulting	in	wide	intervals	required	to	cover	the	pooled	estimate	for	this	subgroup.
This	artefact	disappears	in	fixed-effects	models,	which	were	not	used	in	this	study	due	to	high
heterogeneity	between	the	studies.	We	did	not	review	the	impact	of	delay	to	diagnosis	as	this	was
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recently	reviewed	by	Yi	et	al	[5].
Conclusion
The	diagnostic	delay	across	the	world	is	6.8	years	on	average	in	axSpA,	which	is	significantly	longer
than	2.6	years	for	PsA.	Although	delay	has	improved	over	time	in	some	parts	of	the	world,	many
countries	such	as	the	UK	need	additional	efforts	to	improve	delay	to	diagnosis.	Lower	education
levels,	absence	of	EAMs	and	younger	age	of	onset	were	associated	with	longer	delays;	therefore,
improved	education	for	physicians	and	patients	with	back	pain	may	help	reduce	diagnostic	delay.
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Figure	1
Pooled	estimate	of	diagnostic	delay	in	axial	spondyloarthritis	(including	ankylosing
spondylitis).	Results	ordered	according	to	geography	and	year	of	publication.
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Figure	2
Pooled	estimate	of	diagnostic	delay	in	psoriatic	arthritis	and	spondyloarthritis.
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